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Abstract
 
Neisseria meningitidis
 
 is a human pathogen, which, in spite of antibiotic therapy, is still a major
cause of mortality due to sepsis and meningitis. Here we describe NadA, a novel surface anti-
gen of 
 
N. meningitidis
 
 that is present in 52 out of 53 strains of hypervirulent lineages electro-
phoretic types (ET) ET37, ET5, and cluster A4. The gene is absent in the hypervirulent lineage
III, in 
 
N. gonorrhoeae
 
 and in the commensal species 
 
N. lactamica
 
 and 
 
N. cinerea
 
. The guanine/cy-
tosine content, lower than the chromosome, suggests acquisition by horizontal gene transfer
and subsequent limited evolution to generate three well-conserved alleles. NadA has a pre-
dicted molecular structure strikingly similar to a novel class of adhesins (YadA and UspA2),
forms high molecular weight oligomers, and binds to epithelial cells in vitro supporting the
hypothesis that NadA is important for host cell interaction. NadA induces strong bactericidal
antibodies and is protective in the infant rat model suggesting that this protein may represent a
novel antigen for a vaccine able to control meningococcal disease caused by three hyperviru-
lent lineages.
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Introduction
 
Neisseria meningitidis
 
 is a capsulated gram-negative bacte-
rium, which is a major cause of meningitis and sepsis, two
devastating diseases that can kill children and young adults
within hours despite the availability of effective antibiotics.
The bacterium is found only in humans and is classified
into 13 serogroups on the basis of the chemical composi-
tion of the capsular polysaccharides. Five serogroups (A, B,
C, Y, and W-135) cause disease (1, 2). The strains, isolated
from invasive meningococcal disease, have been classified
by multilocus enzyme electrophoresis into a small number
of hypervirulent lineages: electrophoretic types (ET)
 
*
 
ET37, ET5, cluster A4, lineage III, and subgroups I, III,
and IV-1 (3, 4). Recently, a new sequence-based classifica-
tion, multilocus sequence typing, has been introduced,
which classifies the above strains into sequence types (ST)
ST11, ST32, ST8, ST41, ST1, ST5, and ST4, respectively
(5). Strains isolated from healthy carriers usually fall into
many different ET and ST types.
The reported annual incidence of meningococcal disease
varies from 0.5 to 10 per 100,000 persons; however, during
epidemics the incidence can rise above 15 and up to 400
per 100,000. The case fatality rate ranges from 5 to 15%,
and up to 25% of survivors are left with neurological se-
quelae. The first successful vaccines against meningococcus
consisted of purified polysaccharides against four (A, C, Y,
and W-135) of the five pathogenic serogroups (6–8). These
vaccines are highly effective in adults but less efficacious in
infants and young children, the age groups mostly exposed
to disease. Second generation glycoconjugate vaccines have
recently been introduced against serogroup C. meningo-
coccus
 
 
 
(9, 10). These vaccines have shown extremely high
efficacy (
 
 
 
90%) in infants, children, and adolescents and
are presently a valid measure to eliminate the disease caused
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by serogroup C. Similar vaccines against serogroups A, Y,
and W-135 are in the later phases of development (11).
Currently, there are no licensed vaccines available in the
U.S. and Europe for the prevention of serogroup B 
 
N.
meningitidis
 
 (MenB) disease, which is responsible for 32% of
all meningococcal disease in the United States and for 45–
80% of the cases in Europe and for 
 
 
 
50% of the cases in
the rest of the world, with the exception of sub-Saharan
Africa where serogroup A is responsible for 90% of the
cases (12, 13). The use of capsular polysaccharide as the ba-
sis of a vaccine for prevention of MenB diseases has been
problematic because the MenB capsular polysaccharide is
identical to a widely distributed human carbohydrate
(
 
 
 
[2
 
→
 
8]
 
N
 
-acetyl neuraminic acid or polysialic acid), which
is a self-antigen, and therefore, is poorly immunogenic in
humans. Furthermore, the use of this polysaccharide in a
vaccine may elicit autoantibodies (14, 15). An alternative
approach to vaccine development is based on surface-
exposed proteins contained in outer membrane vesicles.
These vaccines have been shown both to elicit serum bac-
tericidal antibody responses and to protect against menin-
gococcal disease in clinical trials (4, 16). Although outer
membrane vesicle vaccines have been used for vaccination
in Central and South America, they have limitations that
prevented their use in other countries. Their main problem
is that the major protein antigens show sequence and anti-
genic variability (17, 18) and, although they induce protec-
tive antibodies against the homologous strain, they fail to
induce protection against heterologous strains (19).
Recently our laboratory published the use of the ge-
nomic sequence to discover novel antigens capable of in-
ducing protection against MenB (20). During the screening
of the genome, we found a protein, NMB1994, able to
elicit bactericidal antibodies, which has the same carboxyl
terminal region architecture as YadA and UspAs. Since Us-
pAs are promising protective antigens against 
 
M. catarrhalis
 
infection (21) and YadA has been implicated in virulence
(22), we further investigated this protein. Here we describe
NMB1994 (NadA) a novel surface-exposed oligomeric
protein, which binds to host cells in vitro suggesting that it
could belong to this novel class of adhesins. NadA is en-
coded by an open reading frame (ORF) that was found in
the genome of the meningococcus B strain MC58 (23) and
was absent in the genome of the meningococcus A strain
Z2491 (24). We show that the gene is present in a subset of
 
N. meningitidis
 
 strains but is overrepresented in three hyper-
virulent lineages and may represent a new antigen for vac-
cine development and a tool to dissect the evolution and
pathogenic mechanisms of this bacterium.
 
Materials and Methods
 
Computer Analysis.
 
Computer programs included in the Uni-
versity of Wisconsin Genetics Computer Group (GCG) sequence
analysis package (v10.0) and the Biosoft Sequence Processor
GeneJockey II were used to analyze and compare the nucleotide
sequences from different Neisseria strains.
 
Sequence homology searches, protein features, and possi-
ble functions were performed using the programs BLAST,
SignalP (25), SIMPA96 (26), PAIRCOIL (27), ZZIP (28), and
CLUSTALW.
 
Nucleotide Sequence Accession Nos.
 
The complete genome se-
quences of 
 
N.
 
 
 
meningitidis
 
 serogroup B strain MC58 (23) and 
 
N.
meningitidis
 
 A strain Z2491 (24) are available under GenBank/
EMBL/DDBJ accession nos. AE002098 and AL157959. The nu-
cleotide sequences of 
 
nadA
 
 genomic region of each strain ana-
lyzed have been submitted to the GenBank database GenBank/
EMBL/DDBJ accession nos. AF452465–AF452488.
 
Bacterial Strains, Culture Conditions, and Chromosomal DNA Iso-
lation.
 
175 
 
N. meningitidis
 
 strains were chosen for analysis. For a
detailed list, see Online Supplemental Material.
Bacteria were grown overnight at 37
 
 
 
C in a humidified atmo-
sphere of 5% CO
 
2
 
 in air on gonococcus (GC) medium agar
(Difco) supplemented with Kellogg’s supplement solution (0.22 M
D-glucose, 0.03 M 
 
L
 
-glutamine, 0.001 M ferric nitrate, and
0.02 M cocarboxylase; Sigma-Aldrich) as described previously
(29, 30). One loopful of meningococci was dissolved in 500 
 
 
 
l of
PBS and chromosomal DNA was prepared as described previ-
ously (31).
 
PCR and Nucleotide Sequencing of Gene Fragments.
 
PCR am-
plification of the 
 
nadA
 
 genes were performed on 10 ng of chro-
mosomal DNA using primers, mapping 350 nt upstream and
downstream the coding region (forward primer: GTC-
GACGTCCTCGATTACGAAG; reverse primer: CGAGGC-
GATTGTCAAACCGTTC), and Platinum Hifi Taq Poly-
merase (GIBCO BRL). PCR conditions were: 30 cycles of
denaturation at 95
 
 
 
C for 30 s; annealing at 60
 
 
 
C for 30 s; and
extension at 68
 
 
 
C for 1 min. PCR products were analyzed on
1% agarose gel and the sizes were determined using a molecular
weight marker 1-Kb Plus DNA Ladder (GIBCO BRL). The
amplified fragments were purified on a Qiaquick column
(QIAGEN) and then automated cyclo-sequenced (model 377;
Applied Biosystems) by primer walking on both strands of the
amplified fragment.
 
Cloning, Expression, and Purification of rNadA.
 
The 
 
nadA
 
 se-
quences (allele 1: aa 24–362; allele 2: aa 24–343; allele 3: aa 24–
350), were amplified by PCR on chromosomal DNA and cloned
into pET21b
 
 
 
 vector (Novagen). The plasmids were transformed
in 
 
Escherichia coli
 
 BL21 (DE3) to express the proteins as COOH-
terminal Histidine fusions. Protein expression was induced at
30
 
 
 
C by adding 1 mM IPTG at OD
 
600nm
 
 0.3 and growing the
bacteria for an additional 3 h; expression was evaluated by SDS-
PAGE. Recombinant fusion proteins were purified by affin-
ity chromatography on Ni
 
2
 
 
 
-conjugated chelating fast-flow
Sepharose 4B resin (Amersham Pharmacia Biotech).
 
Western Blot Analysis.
 
Bacterial colonies were grown to sta-
tionary phase in GC broth supplemented with 0.3% glucose.
Samples were taken at different times, pelleted by centrifugation
at 3,000
 
 
 
 
 
g
 
 for 10 min, resuspended in PBS, and thawed/frozen
up to bacterial lysis. Equal amounts of proteins were subjected to
SDS-PAGE on 12.5% polyacrylamide gels and electrotransferred
onto nitrocellulose membranes.
 
Dot Blotting.
 
The presence of 
 
nadA
 
 gene in 50 strains out of
the 175 strains was tested by dot-blot. We used as probe the
whole 
 
nadA
 
 gene, as amplified from 2996 strain (allele 3) and la-
beled with digoxigenin using the Roche DIG High-Prime DNA
Labeling and Detection kit. 10 
 
 
 
l aliquot of cell suspension of
each strain were boiled for 10 min and spotted on nylon mem-
brane (Boehringer Mannheim). The membranes underwent
cross-linking of DNA by 2
 
 
 
 exposure to UV light and other stan- 
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dard procedures for preparation and signal detection as reported
by the manufacturer.
 
Preparation of Polyclonal Anti-NadA Antisera.
 
To prepare anti-
sera, 20 
 
 
 
g of purified recombinant proteins were used to immu-
nize 6-wk-old CD1 female mice (Charles River Laboratories).
4–6 mice per group were used. The proteins were given intra-
peritoneally, together with CFA for the first dose and incomplete
Freund’s adjuvant for the second (day 21) and third (day 35)
booster doses. Bleed out samples were taken on day 49 and used
for the serological analysis.
50 
 
 
 
g of purified rNadA from allele 3 were used to immunize
guinea pigs. Two animals per group were used. The immuniza-
tion was performed subcutaneously together CFA for the first
dose and complete Freund’s adjuvant for the further three doses
(days 28, 56, and 84). Bleed out samples were taken on day 105
and used for the animal protection assay.
 
Binding of Antisera to the Surface of Meningococci.
 
The ability of
mouse polyclonal anti-rNadA antisera to bind to the surface of live
meningococci was determined using FACScan™ flow cytometer
of the encapsulated NMB and its isogenic nonencapsulated mu-
tant M7 strains (32). We used R-phycoerythrin-conjugated
goat F(ab)
 
2
 
 antibody to mouse Ig (Jackson ImmunoResearch
Laboratories) to detect antibody binding.
 
Complement-mediated Bactericidal Activity.
 
Serum bactericidal
activity against 
 
N. meningitidis
 
 strains was evaluated as described
previously (20, 33), with pooled baby rabbit serum (CedarLane)
used as complement source. Serum bactericidal titer, was defined
as the serum dilution resulting in a 50% decrease in CFUs per ml
after 60 min incubation of bacteria in the reaction mixture, com-
pared with control CFU per ml at time 0. Typically, bacteria in-
cubated with the negative control antibody in the presence of
complement showed a 150 to 200% increase in CFU/ml during
the 60 min of incubation.
 
Animal Protection.
 
The ability of anti-NadA Abs (guinea pigs
antisera) to confer protection against 
 
N. meningitidis
 
 bacteremia
was evaluated as previously described in infant rats challenged in-
traperitoneally (34). Briefly, 5–7-d-old pups from litters of out-
bred Wistar rats (Charles River Laboratories) were randomly re-
distributed to the nursing mothers. Two experiments were
performed using two different MenB strains (8047 and 2996).
Each strain has been serially passaged three times in infant rats. In
experiment 1, groups of four were challenged intraperitoneally
with 100 
 
 
 
l of a mix of bacteria from strain 8047 (7 
 
 
 
 10
 
3
 
 CFU)
and heat inactivated guinea pig antiserum or control mAb. In ex-
periment 2, group of six animals were treated with the mAb or
different dilutions of guinea pig antiserum at time 0. 2 h later,
they were challenged with the bacteria from strain 2996. The an-
ticapsular control mAb used was SEAM 3 (35). In both experi-
ments, blood cultures were obtained 18 h after the challenge, by
puncturing the heart with a syringe and needle containing 
 
 
 
25 U
of heparin without preservative (Fuijisawa). Bacteria numbers
in the blood cultures were obtained by plating out 1, 10, and 100
 
 
 
l of blood onto chocolate agar overnight. For calculation of
geometric mean CFU/ml, animals with sterile cultures were as-
signed a value of 1 CFU/ml.
 
Binding Assay.
 
Chang epithelial cells (Wong-Kilbourne de-
rivative, clone 1–5c-4, human conjunctiva) were maintained in
DMEM (GIBCO BRL) supplemented with 10% heat-inacti-
vated FCS, 15 mM 
 
L
 
-glutamine, and antibiotics. Cells were non-
enzymatically detached using cell dissociation solution (Sigma-
Aldrich), harvested, and resuspended in RPMI 1640 medium
supplemented with 1% FBS. 5 
 
 
 
 10
 
4
 
 cells were mixed with
rNadA (allele 3), rGNA2132 proteins, devoid of the COOH-
terminal Histidine fusion or medium alone, and incubated 30
min at 4
 
 
 
C. Cells were incubated with antisera on ice for 1 h,
then for 30 min on ice with R-phycoerythrin-conjugated goat
F(ab)
 
2
 
 antibody to mouse Ig. Cells were analyzed with a FAC-
Scan™ flow cytometer. The mean fluorescence intensity for each
population was calculated.
 
Online Supplemental Material.
 
Characteristics of the 175 
 
N.
meningitidis
 
 strains analyzed in this study.
 
Results
 
A Coiled-Coil Protein Anchored to the Outer Membrane.
 
During the screening of the 
 
N. meningitidis
 
 genome for
novel vaccine candidates (20), 
 
nadA
 
 (
 
nmb1994
 
) was found
to be one of the ORFs encoding a protein able to elicit se-
rum bactericidal antibodies in mice. This ORF encodes a
predicted outer membrane protein with 32–34% identity
to the ubiquitous surface protein A2 of 
 
M. catarrhalis
 
(UspA2; reference 36) and to an adhesin-invasin expressed
by enteropathogenic 
 
Yersinia
 
 species (YadA), respectively
(37, 38).
NadA is a protein of 362 amino acids with a possible
leader peptide of 23 amino acids. The mature protein has a
predicted molecular weight of 35363.49 daltons and an iso-
electric point of 4.50. Analysis of the predicted secondary
structures revealed several features that are summarized in
Fig. 1. The COOH-terminal region (aa 310–362) has a
predicted amphipatic 
 
 
 
-structure, and a terminal aromatic
amino acid, which are typical features of outer membrane
anchoring domains (39). The amino terminal region (aa
23–90) has not a defined secondary structure, whereas the
rest of the protein has mainly an 
 
 
 
-helix propensity
(84.6%). Within this region, residues from 90–146 and
183–288 have high probability of forming coiled coils. In
addition, residues 122–143 contain four leucine residues in
the “a” positions of the heptad repeats (L-x[6]-L-x[6]-L-
x[6]-L) that may form a leucine zipper domain. It is known
that both coiled coils and leucine zipper sequences are in-
volved in dimerization (40) and may mediate oligomeriza-
tion of monomers via association of two or more 
 
 
 
 helices.
Figure 1. Schematic illustration of the possible NadA topology and
corresponding domain structure. The globular amino (N) termini and the
amphipatic COOH (C) termini are indicated. The positions of the leader
peptide (LP), the coiled-coil structure and the membrane anchor are
shown. Leucine zipper is indicated by black ovals and the   strands by
dark vertical lines. The amino acid sequence below shows the leucine
zipper motif and the leucine repeat highlighted in black. 
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A closer examination of the amino acid homology of
NadA with YadA and UspA2 revealed that similarity is
mainly clustered in the COOH terminal region (56–63%
identity in the last 70 amino acids, respectively). Outside
this region the level of identity drops to 23–25%. Interest-
ingly, the overall similarity is conserved at secondary struc-
ture level. In fact, YadA and UspA2 have a COOH termi-
nal membrane anchor made by four amphipatic 
 
 
 
-strands
(41), and an 
 
 
 
-helical internal region with a propensity to
form coiled-coils. Two putative leucine zippers are present
in UspA2 (36), but they are absent in YadA. In the case of
YadA and UspA2 it has been shown that the 
 
 
 
-helices
form coiled-coils regions, which mediate oligomerization
of monomers (41, 42). The absence of cysteine residues in
the mature forms of NadA is another feature common to
its homologues.
 
A Foreign Gene Present in a Subset of Hypervirulent
Strains.
 
The 1,086 base pairs 
 
nadA
 
 coding region is
flanked at the 3
 
  end by a terminator sequence while at the
5  end (Fig. 2 A) it shows a putative ribosome-binding site
(5 -AAGG-3 ) and a putative promoter region located 8
and 47 base pairs, respectively, upstream the ATG start
codon. 130 nucleotides upstream the coding region we
find nine repeats of the tetranucleotide TAAA, preceded
by a second putative promoter with –10 and –35 regions.
Because of the presence of the TAAA repeats, the gene had
been listed as one of those that may undergo phase varia-
tion, even though the repeats are not in the coding region
(23). The G C content of the nadA gene and its upstream
region is lower than average (45% against an average of
the rest of the genome, 51.5%), suggesting acquisition of the
gene by horizontal transfer. Remarkably, the gene and the
upstream region are not present in the published sequence
of the genome of serogroup A, strain Z2491 (24). In this
genome, a short sequence of 16 nucleotides with no ho-
mologies in the database, replaces the nadA gene (Fig. 2 B),
whereas the upstream and downstream genes (nmb1993
and nmb1995) are well conserved (91 and 97% identity).
Analysis of the sequences immediately adjacent to the nadA
region and absent in the Z2491 A strain shows that the seg-
ment is flanked by the TCAGAC direct repeats. This may
indicate a mechanism of recombination. In the A strain, the
stretch of 16 nucleotides has a disrupted pair of TCAGAC
repeats flanking it.
To assess the presence of the nadA gene in the N. menin-
gitidis population, 150 isolates, representative of the five
disease-associated serogroups (A, B, C, Y, and W-135),
were screened by PCR and/or dot blot hybridization. In
addition, 25 strains isolated from healthy carriers were
tested (Online Supplementary Data). The analysis also in-
cluded one strain each of N. gonorrhoeae, N. cinerea, and N.
lactamica. 47% of the isolates examined were positive for the
presence of nadA. The gene was present in 52 out of 53
strains of the hypervirulent lineages ET5, ET37, and cluster
A4, whereas it was absent in all the tested lineage III strains.
Seven of the 25 carrier strains were positive (unpublished
data. nadA was absent in N. gonorrhoeae and in the com-
mensal species N. lactamica and N. cinerea.
Three Well-Conserved Alleles of nadA. PCR amplification
was performed by using primers located in the conserved
regions upstream and downstream nadA. PCR products of
roughly 1,800 nucleotides, slightly different in size depend-
ing on strains, were obtained when the nadA gene is
present (Fig. 3, lanes 1–3), whereas PCR products of 400
nucleotides were obtained in the absence of the gene (Fig.
3, lane 5). Four strains generated an atypical PCR product
higher than that expected (Fig. 3, lane 4).
We determined the nucleotide sequence of 36 strains
representative of each size: 26 positive strains; four strains
generating an atypical PCR product; and six negative
strains. In the negative strains, we found the nucleotide
sequence of 16 base pairs, identical to the one present in
the published sequence of the genome of serogroup A,
strain Z2491. The positive strains have a nadA gene size
ranging from 1,086 to 1,215 base pairs with consequent
variation of the amino acid sequences of the encoded pro-
teins from 362 to 405 amino acids. It is possible to cluster
Figure 2. (A) Nucleotide sequence of the nadA upstream region. Puta-
tive –35 and –10 domains and a possible ribosomal binding site (RBS) are
indicated. The translation start codon is reported in bold. The nine re-
peats of the tetranucleotide TAAA are highlighted in black. (B) Sche-
matic comparison of the genome region organization in B strain MC58
and A strain Z2491. DR, direct repeat.
Figure 3. PCR products from positive strains (MC58, 90/18311,
2996; lanes 1–3), negative strains (NG3/88; lane 5), and from strains giv-
ing an atypical result (L93/4286; lane 4).1449 Comanducci et al.
22 of the 26 nadA genes into three alleles (Table I and Fig.
4). The sequence of the gene within each allele is identical
and the overall identity between the alleles ranges from 96
to 99%. Allele 1, coding for a protein of 362 amino acids,
is contained by all the ET5 strains sequenced and recent
isolates for which ET-type is not yet available. However,
their serotype and serosubtype are typical of the ET5
complex. Allele 2, coding a protein of 398 aa, is contained
by all the ET37 strains, one strain of cluster A4, and three
additional not ET-typed serogroup C strains. Allele 3,
coding a protein of 405 aa, is contained by serogroup A,
B, and C strains. As shown in Fig. 4, the three alleles differ
by a few amino acid changes and by a 7 or 43 amino acid
deletion/insertion.
Interestingly, all deletion/insertion happen in the coiled-
coil region and involves 7 or 43 amino acids which, repre-
senting two or six turns of the  -helix, allow for variations
in length of the coiled-coil region without disturbing the
overall structure. Furthermore, the 7 aa deletion in the al-
lele 2 results in the loss of the first heptad repeat of the leu-
cine zipper domain but does not destroy the domain be-
cause leucine residues at a fixed spacing of seven residues
can be replaced mostly by Met, Val, or Ile. In this case al-
lele 2 could use the Ile upstream or downstream to form
the leucine zipper motif (Fig. 1).
The remaining four positive strains are minor variants of
the alleles (indicated by asterisks in Table I). Two of them
have a single amino acid mutation in the leader peptide,
one has an additional 7 amino acids deletion and one is a
recombinant (chimera) of alleles 1 and 2.
Finally, the four strains, which generated an atypical
PCR product, contain one copy of the insertion sequence
IS1301. The insertion site was identical, and the increase
in length of the PCR sequence was in keeping with the
size of the insertion element. The orientation of IS1301
differed in the four isolates indicating an independent
event. The target consensus for IS1301, 5 -AYTAG-3 
(43), was found within the nadA gene at nucleotide 472
Table I. Characteristics of 26 N. meningitidis and their NadA Gene Allele
Strain
Serogroup
type: subtype Clonal group NadA allele (TAAA) repeats NadA expression
64/69 NG:15:P1.7,16 ET5 1 4  
BZ83 B:15 ET5 1 5    
CU385 B:4:P1.15 ET5 1 6   
MC58 B:15:P1.7,16b ET5 1 9  
BZ169 B:15:P1.16 ET5 1 12   
95330a B:4:P1.15 ET5 1 9 ND
ISS1104 B:15:P1.7,16 ND 1 4  
ISS1071 B:15:P1.7,16 ND 1 5    
ISS832 B:15:P1.7 ND 1 5   
NM119 B:4.P1.15 ND 1 6 ND
NM066 B:15:P1.7,16 ND 1 12 ND
90/18311 C:NT:P1.5 ET37 2 9   
NGP165 B:NT:P1.2 ET37 2 9   
FAM18 C:2a:P1.5,2 ET37 2 9 ND
M986 B:2a:P1.5,2 ET37 2 12   
ISS1024a C:2b:P1.5 ND 2 9   
ISS838 C:2a:P1.5,2 ND 2 6   
PMC8 C ND 2 10     
961-5945 B:2b:P1.21,16 A4 2 12    
ISS759a C:2b:P1.2 ND 3 8     
F6124 A subgroup III 3 9  
NMB B:2b:P1.5,2 ND 3 12   
8047 B:2b:P1.2 ND 3 12    
2996 B:2b:P1.5-1,2 ND 3 12    
C11 C:NT:P1.1 ND 3 12    
973-1720a C:2b:P1.2 A4 3 12    
aMinor variants of the alleles.
ND: not done.1450 Neisseria meningitidis Surface Protein
generated by an A to G mutation, and was accompanied
by a TA duplication.
Sequence analysis of the putative promoter region shows
that the number of the tetranucleotide repeat (TAAA) varies
from 4 to 12 in different strains (Table I). The sequence
polymorphism of the nadA flanking regions (50 bases up-
stream the putative promoter and 350 bases downstream the
terminator regions) segregates with each allele, respectively.
The Protein Forms High Molecular Weight Oligomers.
Western blots of whole-cell lysates of all N. meningitidis,
probed with anti-NadA antibodies, showed a high molecu-
lar weight reactive band in all strains containing the gene
(Fig. 5, lanes 1–3), absent in the negative strains (Fig. 5,
lane 5). Boiling of the sample buffer up to 40 min did not
change the pattern (data not shown). The different size of
the proteins was consistent with the size of the alleles.
Given the expected size ranging from 35 to 40 kD of the
monomeric proteins, the high molecular weight of the ob-
served band could be explained by the presence of an oli-
gomeric form of NadA. This possibility is supported by the
fact that in a strain containing the IS1301, coding for a
shorter protein of 162 amino acids and lacking most of the
coiled-coil region, the high molecular weight reactive band
was absent and replaced by a band of 14.5 kD (Fig. 5, lane
4), consistent with the predicted molecular weight of the
processed monomeric protein. Whereas the oligomeric
protein was found in all strains containing a functional
gene, the expression level varied from strain to strain (Ta-
ble I). Moreover, the amount of NadA protein varied
within the same strain during growth.
Four different strains (MC58, 2996, C11, and F6124),
chosen as representative of diverse overall NadA expression
level, were followed during growth up to stationary phase.
The growth of two of the tested strains (MC58 and 2996,
low and high NadA expression level, respectively) is shown
in Fig. 6. Western immunoblot of samples corresponding
to each time point of the bacterial growth curve showed
that the NadA band was barely visible at the beginning of
the growth and became more intense during growth, up to
its maximum, at stationary phase. All strains analyzed
showed the same growth phase–dependent behavior.
The Protein Is Surface-exposed and Represents a Target for
Bactericidal Antibodies. Western blot of outer membrane
vesicles fraction (data not shown) revealed the presence of a
high molecular weight band corresponding to the oligo-
meric form of NadA supporting the hypothesis that the oli-
gomer is anchored to the outer membrane. Furthermore,
FACS® analysis showed that NadA was available for anti-
body binding on the surface of bacteria. The analysis was
performed on live bacteria during the logarithmic phase of
growth, using antibodies against the recombinant protein.
The encapsulated NMB and the nonencapsulated isogenic
mutant M7 were used. As shown in Fig. 7, polyclonal anti-
NadA antibodies were able to bind to both strains, al-
though in the nonencapsulated M7 strain the peak of fluo-
rescence was one log higher than in the capsulated strain.
These data indicate that the protein is exposed on the sur-
face of the bacterium and available for binding both in the
presence and in the absence of the polysaccharide capsule.
However, the presence of the capsule hinders the binding
of the antibody.
We also tested whether the anti-NadA serum had bac-
tericidal activity against a panel of strains. As shown in Ta-
Figure 4. Sequence comparison of NadA polypeptides representative
of each of the genetic variants. Differences in amino acids are indicated.
Empty boxes represent deletions. The leader peptide, the coiled-coil
structure, and the membrane anchor are shown.
Figure 5. Western immunoblot of whole-cell lysates of strains repre-
sentative of each NadA allele. M, molecular size marker; lane 1, strain
MC58 (allele 1); lane 2, strain 90/18311 (allele 2); lane 3, strain 2996
(allele 3); lane 4, strain L93/4286 (IS1301); lane 5, strain NG3/88 (nega-
tive). Arrows indicate the diverse forms of the NadA protein.1451 Comanducci et al.
ble II, the serum induced complement-mediated killing of
all strains that have the nadA gene, and was inactive
against the strains that do not have the gene. However,
the bactericidal titers varied between strains. Titers were
higher against strains expressing higher amounts of pro-
tein. This result was confirmed when bactericidal titers
were determined in the early and late phase of growth
(Fig. 6). To check whether the differences in the bacteri-
cidal activity were due to different allele sequences, im-
mune sera, raised against the three NadA types, were pro-
duced and used in a cross-bactericidal assay. The results
obtained with the antisera were similar to those shown in
Table II, suggesting that the bactericidal activity is not in-
fluenced by the allele diversity but rather to the antigen
expression level. We also tested the ability of the immune
sera to protect animals during infection using the infant rat
model and found that the serum is highly protective in
this assay (Table III).
The NadA Protein Binds to Epithelial Cells. To investi-
gate the biological function of NadA and its ability to in-
teract with host cells in vitro, we used FACS® analysis to
test whether NadA could bind to Chang epithelial cells.
Purified recombinant protein was added at increasing con-
centration to Chang epithelial cells and binding was mea-
sured. As shown in Fig. 8 A, cells incubated with NadA
exhibited a peak of fluorescence, which was absent when
cells were incubated with medium alone. Binding of NadA
was concentration dependent, reaching the plateau at
200   g/ml (Fig. 8 B). Unrelated recombinant protein
GNA2132 (20) failed to bind cells even at a concentration
of 400  g/ml.
Discussion
We have identified a novel meningococcal antigen,
NadA, which has a predicted molecular structure strikingly
similar to the known virulence-associated factors YadA and
UspA2 (41). NadA has the capacity of forming oligomers
anchored to the outer membrane, the ability to interact
with host cells in vitro, and evokes a strong bactericidal ac-
tivity. Furthermore, the gene is present in three of the four
hypervirulent lineages of serogroup B and C strains. All
these features suggest an important role of NadA in the
multifactorial virulence expressed by meningococci.
Gene Presence and Evolution. The gene is present in
 50% of N. meningitidis strains surveyed, representative of
all the major disease-associated serogroups. Sequence anal-
ysis of the nadA gene reveals the presence of three well-
defined alleles, which are well conserved among each other.
Given the extreme variability of surface-exposed proteins
in N. meningitidis, the conservation among the alleles is sur-
prising and suggests a weak selective pressure. The low GC
content of the region is consistent with horizontal gene
transfer. It would be interesting to know when the gene
was acquired by meningococcus and follow the evolution
of this gene. Our data show the presence of the gene since
Figure 6. Growth phase–dependent NadA expression of MC58 and
2996 strains. (Left) Western immunoblot of samples corresponding to
each time point of the bacterial growth curve (right). M, molecular size
marker; absorbance at 600 nm at different time during growth; NG3/88,
negative control. Arrows indicate the multimeric forms of the NadA pro-
tein. (Right) Growth curves and bactericidal titers determined in the early
and late phase of growth.
Figure 7. FACS® analysis showing binding of mouse polyclonal anti-
rNadA antiserum to live heterologous nonencapsulated (M7) or encap-
sulated (NMB) N. meningitidis strains. Gray profiles show binding of pre-
immune serum; black profiles show binding of immune serum.
Table II. Bactericidal Activity of Mouse Polyclonal Anti-rNadA 
(Allele 3) Antisera Against Different N. meningitidis Strains
Strain NadA expression Allele Bactericidal titer
2996     3 32768
C11     3 16384
F6124   3 4096
MC58   1 8192
BZ232   -  4
NGH38   -  41452 Neisseria meningitidis Surface Protein
1963, and basically, there is not any sequence variation
within the same alleles in strains isolated in the year 2000
(Online Supplemental Material).
Interestingly, the percentage of nadA presence rises to
 100% in a subset of the hypervirulent lineages. The gene
is always present in the ET5 complex and cluster A4, and
nearly always present in the ET37 complex, whereas lin-
eage III strains are always negative. Lineage III has only re-
cently been introduced in Europe and the U.S. and the
geographic segregation in New Zealand for many years
could have impaired its ability to acquire novel genes. The
sequence polymorphism of the chromosomal flanking re-
gions segregates differentially with each allele (data not
shown). Assuming that recombination at nadA locus uses
the chromosomal flanking regions as recognition sites, we
can hypothesize that mutations have occurred in these re-
gions preventing lineage III from further recombination
events. Another possible explanation is that ET5, ET37,
and cluster A4 strains need nadA to achieve their fitness
peak, whereas lineage III isolates could not derive any sig-
nificant benefit from nadA insertion, thus undergoing a
negative selection.
Gene and Protein Features. The different number of the
DNA tetranucleotide repeat elements (TAAA) located in
the putative promoter region, could associate with phase
variation and influence transcription of the gene, hence its
expression. Indeed, the protein is always expressed even if
at different levels in different strains, but this does not cor-
relate in an obvious manner to the different number of re-
peats. Interestingly, the homologous gene UspA2 has a tet-
ranucleotide repeat (AGAT), located in the same position
as nadA, which varies in different strains (42). The overall
expression of NadA varies during growth reaching its max-
imum at cellular stationary phase.
NadA forms surface-exposed oligomers, which are stable
to heat, SDS, and reduction with  -mercaptoethanol.
Since the mature form of these proteins lack cysteine resi-
dues, disulphide bond formation cannot be involved in this
phenomenon; rather this is consistent with the predicted
coiled-coil structure and the presence of leucine zipper
motifs that might mediate intermolecular interactions be-
tween monomers (44, 45). The size of the oligomers is
 170 kD, suggesting a tetrameric structure. However, a
rigid coiled-coil structure is likely to have an anomalous
migration is SDS-PAGE and therefore, trimeric forms are
also possible.
Antigen Features. The predicted molecular structure,
the capacity of forming oligomers anchored to the outer
membrane, and the ability of the purified protein to inter-
Table III. Anti-NadA Antibody Passive Protection in Infant Rats Challenged with N. meningitidis Serogroup B Strains 8047 or 2996
Blood culture at 18 h
Exp.
Strain
(challenge CFU per rat) Treatment
Serum dilution
or dose of mAb
(µg) per rat No. positive/total
CFU/ml
(geo. mean,103)
1 8047 anticapsular mAb 2 0/4  0.001
(7   103) anti-NadA antiserum 1:5 0/4  0.001
PBS plus 1% BSA 5/5 40.17
2 2996 anticapsular mAb 20 1/6 0.003
(5.6   103) anti-NadA antiserum 1:5 1/6 0.002
anti-NadA antiserum 1:25 3/6 0.035
preimmune NadA serum 1:5 6/6 1.683
Figure 8. (A) FACS® analysis showing binding of rNadA or an unre-
lated protein GNA2132, to human Chang cells. Gray profiles show bind-
ing of cells incubated with medium; black profiles show binding of re-
combinant proteins. (B) Concentration-dependent binding of NadA
expressed as net mean fluorescence intensity.1453 Comanducci et al.
act with host cells in vitro, suggest that NadA could belong
to a novel class of adhesins that are established pathogenic-
ity factors as YadA and UspAs. Furthermore, NadA evokes
a strong antibactericidal antibody response.
In conclusion, NadA has several attributes of being a
good vaccine candidate: (i) it is a surface-exposed mole-
cule, possibly involved in bacterial adhesion; (ii) it is
present in at least 50% of the disease-associated strains and
in  100% of three hypervirulent lineages; (iii) it elicits pro-
tective and bactericidal antibodies in laboratory animals;
and (iv) each allele induces cross-bactericidal antibodies. A
vaccine based on NadA will have some potential for con-
trolling outbreaks of meningococcal disease caused by the
three hypervirulent lineages.
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